أعرض في EDS

Supplementary Figure 1 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

التفاصيل البيبلوغرافية
العنوان:	Supplementary Figure 1 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
المؤلفون:	José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo
بيانات النشر:	American Association for Cancer Research (AACR), 2023.
سنة النشر:	2023
الوصف:	Supplementary Figure 1. Treatment and pharmacodynamic assessment schedules.
DOI:	10.1158/1078-0432.22454826
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f2f3ed94a6bd56e383704d713371c7 https://doi.org/10.1158/1078-0432.22454826
Rights:	OPEN
رقم الانضمام:	edsair.doi.dedup.....78f2f3ed94a6bd56e383704d713371c7
قاعدة البيانات:	OpenAIRE

الوصف
DOI:	10.1158/1078-0432.22454826